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Background/aim: We aimed to evaluate wheezing, bronchial asthma (BA), and atopy in premature infants at 2 years of age via a crosssectional study.
Materials and methods: Premature infants at <37 weeks of gestational age (GA) were assessed for atopy by skin-prick test and serum
immunoglobulin E level at 2 years of age. The family’s and infant’s histories of allergy, BA, atopy, and wheezing were obtained by
questionnaire and from hospital records.
Results: There were 98 infants, with mean birth weight (BW) 1517.4 ± 486.5 g and GA 30.8 ± 2.9 weeks. The frequencies of wheezing,
asthma, and bronchopulmonary dysplasia (BPD) were 32.7%, 16.3%, and 14.3%, respectively. Skin-prick tests were positive for 11
subjects, with allergy to cereals for 7 infants, egg for 3, and peanut for 1.
Wheezing was related to GA, BW, respiratory distress syndrome, mechanical ventilation, sepsis, asphyxia, smoking, antenatal steroid,
BA, palivizumab prophylaxis, number of people in the household, and duration of hospitalization (P < 0.05). Wheezing was negatively
correlated to GA. Family history of BA, smoking, and number of people in the household were linked to BA (P < 0.05).
Conclusion: Wheezing was related to degree of premature birth, but BA was linked to BA in the family and smoking. Increased gestation
should improve the infant’s respiratory health up to 2 years of age.
Key words: Atopy, premature, wheezing

1. Introduction
Respiratory morbidity is a major health problem among
premature infants in early childhood (1–3). Premature
infants, particularly those with bronchopulmonary
dysplasia (BPD), have increased risk of chronic respiratory
morbidities (4,5). Recurrent respiratory symptoms
requiring treatment and lung function abnormalities at
follow-up are common for subjects born even late preterm
(6,7). It is suggested that preterm birth increases the risk of
asthma and wheezing disorders during childhood and the
risk of asthma/wheezing disorders increases as the degree
of prematurity increases in a systematic review and metaanalysis (8). Premature infants, especially BPD patients,
experience more hospital readmissions and outpatient and
emergency rooms visits, and are more likely to suffer from
respiratory illnesses and to need bronchodilator therapy
(9,10).
* Correspondence: sevimunal@yahoo.com

Previous studies related to the effect of prematurity on
atopy in early childhood have been inconclusive. While
atopy has not been related to high lifelong prevalence of
respiratory symptoms, persistence of wheezing has been
associated with allergen sensitization in premature infants
(11). Antigen exposure in early life has been supposed to be
associated with long-lasting effects on atopic sensitization.
Thus, allergen sensitization of children born premature can
be assumed to differ from that of children born at term
(1,2). Prematurity at birth was linked with a decreased longterm risk of allergen sensitization (12). Pregnancy length
and very early childhood were reported to be important in
the development of atopy, and timing of the environmental
exposure was of importance for the immune system (13).
The first months of life are supposed to be an enclosed
period of particular vulnerability towards environmental
risk factors, especially exposure to aero-allergens (14).
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In the present study, we aimed to evaluate the effect of
gestational age, birth weight, and perinatal risk factors on
wheezing, bronchial asthma (BA), and atopy in premature
infants at 2 years of age. Atopy was assessed by skinprick test and serum IgE level. Respiratory morbidities,
especially wheezing, atopy, and BA, were determined by a
questionnaire and from hospital records.
2. Materials and methods
A cross-sectional study including premature infants born
before 37 weeks and followed up at our neonatology
outpatient clinic regularly was designed. Information
about the infant’s respiratory morbidity, care, and evolution
during the first two years of life was obtained in a single
interview with the parents at a routine hospital visit for the
child. The information specifically related to significant
illnesses, medications, and intervention services from
the parent was obtained. Hospital admissions of the
infant due to wheezing at any time and requirements
of bronchodilator therapy were also determined from
hospital records.
A questionnaire was implemented to identify the
family’s and infant’s data related to respiratory and atopic
symptoms at the visit. The questionnaire included the
subject’s birth weight (BW), gestational age (GA), postnatal
age, perinatal disorders, parental and family characteristics,
smoking of parents, attendance at school or daycare for
the subject and siblings, breast-feeding, formula and/or
complementary feeding for the first months, vaccination,
palivizumab prophylaxis, history of allergy and/or atopy
for the family and subjects (asthma, eczema, food or drug
allergy, allergic rhinitis, other allergies), medical history
for respiratory disorders, admission to hospital secondary
to respiratory complaints, and therapy for these complaints
and its duration (Appendix).
GA was defined by last menstrual date, ultrasound
examination (in the absence of a menstrual date or when
a difference of 2 or more weeks existed between menstrual
age and that derived sonographically), or the New Ballard
Score (in the absence of obstetrical indexes) (15). Small
for gestational age was defined as a birth weight below
the 10th percentile of Fenton’s fetal growth charts (16).
Bronchopulmonary dysplasia was defined according
to the National Institute of Child Health and Human
Development consensus criteria (17). Proven neonatal
sepsis was defined as any systemic bacterial or fungal
infection documented by a positive blood culture.
Detailed perinatal, natal, early postnatal, and clinical
data of the infants were recorded. The infants were examined
regularly for physical growth, neurodevelopment, and
retinopathy of prematurity at the outpatient clinic of
neonatology. The infants had routine vaccinations and
respiratory syncytial virus (RSV) immunoprophylaxis
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with palivizumab according to the guideline of the
Turkish Neonatal Society. The Turkish Neonatal Society
suggests palivizumab prophylaxis for premature infants
born before 29 weeks of gestation for the first year and for
those diagnosed with BPD for 2 years (18). The infants
were supported by vitamin D until 2 years old and iron
prophylaxis for the first year.
The premature infants at 2 years of age were examined
for possible hypersensitivity or allergic sensitization at the
allergy department. Atopy was verified by skin-prick test
and by measuring serum total IgE level. Total IgE level
was measured by nephelometry (Siemens Healthcare
Diagnostics Products; Marburg, Germany). The infants
with recurrent respiratory symptoms, such as lower airway
obstruction or recurrent wheezing, followed up at the
neonatology outpatient clinic were referred to the allergy
department regardless of age. The children were diagnosed
with BA if they had wheezing, shortness of breath, or
cough attacks exceeding 24 h at least 2–3 times per year.
The skin-prick test was carried out on the back and read
after 15 min. A commercial extract of inhalant allergens
(Dermatophagoides pteronyssinus, D. farinea, Alternaria,
Cladosporium, aspergillus, cockroach, cat and dog dander)
and food allergens (milk, egg, peanut, fish, soy, wheat)
(Stallergenes, Antony, France) were used. Histamine
HCL (Stallergenes) and allergenic extract sterile diluent
(Stallergenes) were used as positive and negative controls,
respectively. Results were assessed as positive if the wheal
mean diameter was 3 mm or more than the reaction of the
negative control.
The ethical committee of our hospital approved the
study and all parents of the participants provided written
informed consent.
2.1. Statistical analysis
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used
for the analysis of the obtained data. The definitions were
provided as number and percentage for discrete variables
and mean and standard deviation for continuous variables.
Multivariate analysis was used to analyze potential
independent effects of several risk factors on wheezing,
atopy, and BA. Pearson’s correlation coefficient was used
to investigate the relationship between two quantitative,
continuous variables. P values less than 0.05 were defined
as statistically significant.
3. Results
There were 98 premature infants evaluated by a
questionnaire, skin-prick test, and measurement of serum
total IgE level at 2 years of age in this study. The mean BW
of the premature infants was 1517.4 ± 486.5 g and mean
GA was 30.8 ± 2.9 weeks. The results of sociodemographic
factors and postnatal data of the subjects are shown in
Tables 1 and 2.
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Table 1. The socio-demographic factors related to infants.
Factor

Result

Birth weight (g) *

1517.4 ± 486.5 (550–3100)

Gestational age (weeks) *

30.8 ± 2.9 (26–36.5)

Postnatal age (months) *

25 ± 1 (24–28)

Mother’s age *

30.7 ± 5.4 (19–43)

Father’s age *

34.4 ± 5.7 (23–51)

Sex **
Female
Male

46 (46.9%)
52 (53.1%)

Delivery route **
Spontaneous vaginal
Cesarean section

17 (17.3%)
81 (82.7%)

Consanguinity **

8 (8.2%)

Number of siblings **

1.2 ± 1 (0–4)

Attendance at daycare **

24 (24.5%)

Sibling at school or daycare **

47 (47.5%)

Breast-feeding **

85 (86.7%)

Breastfeeding duration (months) *

8.6 ± 8.2 (0–30)

Duration of hospitalization * (months)

35.4 ± 28 (2–118)

Number of people in the household *

4.6 ± 1.3 (3–8)

* Mean ± standard deviation (minimum–maximum), ** n (%)

The frequencies of wheezing, BA, and BPD were 32.7%
(n = 32), 16.3% (n = 16), and 14.3% (n = 14), respectively.
Skin-prick tests were negative for 87 subjects (positive
test ratio 11.1%). We determined allergy to cereals for
7 subjects, egg for 3, and peanut for 1. The mean serum
IgE level of the subjects was 58.2 ± 108.2 (5–639) IU/mL.
Serum IgE level was high for 27 subjects (27.6%). There
were 3 infants that could not achieve catch-up growth at
2 years old. The results of infants related to respiratory
outcome, atopy, and BA are shown in Table 3.
We found that wheezing was related to BW, GA,
respiratory distress syndrome (RDS), surfactant therapy,
BPD, invasive ventilation, noninvasive ventilation,
BA, gastroesophageal reflux (GER), smoking at home,
maternal smoking, antenatal steroid therapy for fetal lung
maturation, palivizumab prophylaxis, sepsis, asphyxia,
the number of people in the household, and duration
of hospitalization (P < 0.05) (Table 4). Palivizumab
prophylaxis was applied to 28% of the infants. The
relation between wheezing and palivizumab prophylaxis
was significant (P < 0.001). There was a weak correlation
between wheezing and GA (r = –0.261, P = 0.009), BW (r
= –0.206, P = 0.042), duration of hospitalization (r = 0.228,
P = 0.024), BA (r = 0.634, P < 0.001), and the number of
people in the household (r = 0.208, P = 0.04).

Table 2. The postnatal data of the infants related to prematurity.
Data

Result, n (%)

Respiratory distress syndrome

53 (54.1%)

Surfactant therapy

45 (45.9%)

Invasive ventilation

47 (48%)

Noninvasive ventilation

61 (62.2%)

Bronchopulmonary dysplasia

14 (14.3%)

Antenatal steroid therapy

48 (49%)

Steroid therapy for BPD*

8 (8.2%)

Small for gestational age

7 (7.1%)

Patent ductus arteriosus

22 (22.4%)

Air leak syndrome

1 (1%)

Proven sepsis

48 (49%)

Palivizumab prophylaxis

28 (28.6%)

Intraventricular hemorrhage
Grade 1–2
Grade 3–4

26 (25.6%)
-

ROP ** Grade 3–4 and/or laser

7 (7.2%)

* BPD: Bronchopulmonary dysplasia, ** ROP: Retinopathy of
prematurity
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Table 3. The results of infants related to wheezing, atopy, and
asthma.
Data

n (%)

Formula feeding at any time

82 (83.7%)

Maternal smoking

15 (15.3%)

Smoking at pregnancy
Active
Passive

31 (31.6%)
12 (12.2%)
19 (19.4%)

Smoking at home

49 (50%)

Family history of BA*

29 (29.6%)

Pet ownership

2 (2%)

Family history of allergic rhinitis

15 (15.3%)

Family history of eczema

5 (5.1%)

Wheezing (at any time)

32 (32.7%)

Allergic rhinitis

2 (2%)

Eczema

4 (4.1%)

Gastroesophageal reflux

8 (8.2%)

Bronchial asthma

16 (16.3%)

Skin prick test positive (atopy)

11 (11.1%)

* BA: Bronchial asthma

BA was related to wheezing, family history of BA,
smoking at home, maternal smoking, and the number of
people in the household (P < 0.05) (Table 4). There was a
weak correlation between BA and palivizumab cumulative
dose (r = 0.217, P = 0.032) and the number of people in the
household (r = 0.209, P = 0.039). Premature infants with
BPD had more wheezing attacks (Table 5).
4. Discussion
It is well described that premature infants are at high risk
for respiratory morbidity, i.e. wheezing, childhood allergy,
and BA, later in life (1–4). In this cross-sectional study, we
aimed to evaluate the effects of BW, GA, and perinatal risk
factors on respiratory outcomes, particularly wheezing,
atopy, and BA in premature infants. The frequencies of
wheezing, BA, and atopy were 32.7%, 16.3%, and 11.1%,
respectively. We found that wheezing was related to BW,
GA, RDS, surfactant therapy, BPD, invasive ventilation,
noninvasive ventilation, BA, smoking at home, maternal
smoking, antenatal steroid therapy, palivizumab
prophylaxis, sepsis, asphyxia, the number of people in
the household, and duration of hospitalization. Notably,
there was a weak correlation between wheezing and GA
(r = –0.261, P = 0.009) and BA (r = 0.634, P < 0.001). We
proposed that increasing the length of gestation should
improve the infant’s respiratory health up to 2 years of age.
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Preterm birth increases the risk of BA and wheezing
disorders during childhood and the risk of asthma/
wheezing disorders increases as the degree of prematurity
increases (19). We determined the lesser the gestation,
the higher rate of wheezing attacks (r = –0.261, P =
0.009). There was no such association between BA and
GA. Although respiratory system infections were not
examined in this study, we proposed that wheezing might
be related to nonatopic mechanisms and the result of
perinatal and postnatal events, because we determined
significant relations between wheezing and BW, GA,
antenatal steroid therapy, RDS, surfactant therapy, invasive
ventilation, noninvasive ventilation, sepsis, asphyxia, BPD,
BA, smoking at home, maternal smoking, palivizumab
prophylaxis, the number of people in the household, and
duration of hospitalization.
In premature infants, viral agents, especially RSV,
most commonly cause respiratory system infections in
early childhood, and RSV-induced bronchiolitis has been
associated with wheezing and BA (20–22). Palivizumab
reduces the severity of RSV infection in premature
infants. Prais reported that palivizumab prophylaxis
was associated with reduced wheezing episodes and
hospitalizations during the first 2 years of life in children
born extremely prematurely, but it did not affect pulmonary
outcome at school age (23). Yoshihara stated that
palivizumab prophylaxis administered to preterm infants
33 to 35 weeks’ GA is associated with a significantly lower
incidence of recurrent wheezing during the first 3 years
of life (24). We determined a significant relation between
wheezing and palivizumab prophylaxis (P < 0.001, Table
4). This should be related to immaturity of the subjects and
possibly having more risk factors for wheezing.
There were studies describing atopy with increased
BW (25). A recent analysis by Rzehak et al. observed an
increased incidence of asthma until the age of 6 years with
a high gain of body mass index in the first 2 years in 8
European cohort studies with 12,050 participants (26).
Sonnenschein-van der Voort described increased risk for
wheezing and asthma in children with an increased infant
weight gain (27). Cesarean section has been associated
with the development of asthma and recurrent wheezing
(28). Maternal asthma has been associated with increased
risk of childhood BA (29). We found that BW, delivery
route, gestation, and maternal BA were not related to BA.
As there were a small number of infants, the results were
unsatisfactory.
Premature infants, especially BPD patients, experience
more hospital readmissions and outpatient and emergency
rooms visits, and are more likely to suffer from respiratory
illnesses and to use respiratory drugs (9,10). Vogt
determined increased risk of inhaled corticosteroid
therapy in premature infants at 6–19 years of age (30). We
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Table 4. The factors affecting wheezing and asthma in the premature infants.
Factor

Wheezing (P)

BA* (P)

Birth weight

0.042

>0.05

Gestational age

0.009

>0.05

Respiratory distress syndrome

0.003

>0.05

Surfactant therapy

0.006

>0.05

Invasive ventilation

0.009

>0.05

Noninvasive ventilation

0.001

>0.05

Bronchopulmonary dysplasia

0.035

>0.05

BA*

<0.001

>0.05

Family history of BA*

0.01

0.01

Smoking at home

0.002

0.006

Maternal smoking

0.014

0.007

Antenatal steroid therapy

0.022

>0.05

Palivizumab prophylaxis

<0.001

>0.05

Sepsis

0.001

>0.05

Asphyxia

0.002

>0.05

Number of people in the household

0.04

0.039

Duration of hospitalization

0.024

>0.05

* BA: Bronchial asthma

found no difference in wheezing, atopy, or BA between
premature infants with and without BPD. However, as
the number of infants with BPD was low, it is impossible
to make any comment related to the influence of BPD on
wheezing, BA, and atopy.
There is controversy related to the mechanism of the
association between prematurity and allergy, BA, and
atopy indicated by different studies (7,8,11,12,20,31–35).
The results of various studies and proposed mechanisms
of atopy and allergic disease in premature infants involved
genetic, perinatal origins, and environmental factors (36).
There is evidence that maternal BA increases the risk of
BA in children (29). The relation between childhood
atopy in premature infants and the histories of atopy,
allergic diseases, and BA in the families is not well
defined. Most of the studies revealed no such association
(37). We determined that family history of BA, smoking,
and crowded living environment increased the risk of
BA in premature infants at 2 years of age. Genetic and
environmental factors, such as smoking, together might
increase the risk of BA and allergic sensitization.
The first limitation of our study is the small number of
participants and this might explain the lack of significant
associations between respiratory morbidity and several
factors we analyzed. Future studies with larger samples
are needed to clarify the significance. Second, the majority

of the respiratory outcomes were reported by parents,
a method frequently used in other studies; however, it
creates a potential information bias (38). Third, we had
no control group including term infants. Moreover, we
reported short-term allergic diseases and asthma in
premature infants. It would be better to define the longterm results of allergy and BA. The factors affecting
wheezing, such as viral infections, were not clear in our
study. A higher ratio of wheezing might be related to
viral infections in premature infants. The effects of GER,
BPD, and viral infections should be investigated by welldesigned randomized controlled trials.
In conclusion, wheezing was significantly related to
gestation and perinatal risk factors (BW, RDS, surfactant

Table 5. The relation between bronchopulmonary dysplasia and
wheezing, atopy, and asthma in the premature infants.
Factor

BPD* +

BPD* –

P

Wheezing

8

60

0.035

Bronchial asthma

3

71

>0.05

Atopy

2

75

>0.05

*BPD: bronchopulmonary dysplasia
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therapy, invasive ventilation, noninvasive ventilation,
sepsis, asphyxia, BPD, smoking, antenatal steroid therapy,
palivizumab prophylaxis, number of people in the
household, and duration of hospitalization) in premature

infants at 2 years of age. Wheezing attacks were inversely
related to GA. We suggested that increasing the length of
gestation should improve the infant’s respiratory health up
to 2 years of age.
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Appendix. The questionnaire filled out for every infant.
PREMATURE INFANTS WHEEZING-ATOPY FORM
Name

Age:…..….

Date of birth:

Sex □ F

Address:
□ M

City

Phone:

PRENATAL
Maternal prenatal smoking:

Active

Passive

None

Chronic Disorder:

Vitamin:

No

Yes

Vaccination:

Celestone:

No

Yes

Dose

NATAL
Gestational age: ………week
Multiple pregnancy:

No

Route: Vaginal:
Twins

Birth weight:……..g

C/S:

Triplet

POSTNATAL
Resuscitation: Yes No

RDS: Yes No

Product: Survanta Curosurf

PDA: No Yes
Therapy: Ibuprofen Indomethacin

IMV: Yes No

CPAP: Yes No

IHB: Yes No

Phototherapy:

BPD: Yes No Type:

NEC: Yes No

Asphyxia:

AGA:

Duration of hospitalization:

GER: Yes No Therapy:

ROP: Grade: Zone: Therapy

Steroid for BPD: Yes

PALIVIZUMAB: Age of first dose:
Breast milk: Yes No:

Surfactant: Yes No: … .dose
Surgery
MV duration:
Exchange: Yes No

Yes No

IVH: No Yes Grade

SGA:

LGA:

Duration:

Sepsis: Yes No

No Dose:

Total dose:
D vitamin: Yes No:……. Duration:

Duration:

Multivitamin: Yes No …. Duration:

Formula: Yes No ……… beginning age:

Supplemental food:

Vaccines: Yes-whole No Missing

Kindergarten: No Yes Beginning age

Sibling at kindergarten: Yes No

Sibling at school: Yes No

Recurrent wheezing: Yes No

Asthma: No Yes

Eczema: No Yes

Food allergy: No Yes

Drug allergy: No

Allergic rhinitis: No Yes
Yes

FAMILY
Mother age:

Father age: ……year

Consanguinity: No

Number of sibling:

Number of living at home:

Pet: No

Mother Smoking: No Yes

Smoking at home: No

year

Yes

Yes

Yes

1

ÜNAL et al. / Turk J Med Sci
FAMILY HISTORY OF ALLERGY:
Asthma
Mother

No

Father

No

Siblings

No

Eczema

Food allergy

Allergic rhinitis

Drug allergy

Allergy other

PHYSICAL EXAMINATION:
Weight:

(

Length:

P)

(

P)

Head circumference:

(

P)

Respiratory:

CVS:

GIS:

General:

Neurologic:

Extremity:

BMI:

WHEEZING
Wheezing at any time: No Yes

How many:

Age at first wheezing:

Hospitalization: No

How many:

Therapy:

Yes

BA diagnosed by MD: No Yes

Therapy: No Yes Steroid

month

LTRA

ATTACKS OF WHEEZING:
Age:

Duration:

Therapy:

Hospitalization:

Age:

Duration:

Therapy:

Hospitalization:

Age:

Duration:

Therapy:

Hospitalization:

Age:

Duration:

Therapy:

Hospitalization:

Age:

Duration:

Therapy:

Hospitalization:
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